Exploring the causes of the high incidence of delayed graft function after kidney transplantation in Brazil: a multicenter study.

This retrospective multicenter (n = 18) cohort study evaluated the incidence, risk factors, and the impact of delayed graft function (DGF) on 1-year kidney transplant (KT) outcomes. Of 3992 deceased donor KT performed in 2014-2015, the incidence of DGF was 54%, ranging from 29.9% to 87.7% among centers. Risk factors (lower-bound-95%CI OR upper-bound-95%CI ) were male gender (1.066 1.2491.463 ), diabetic kidney disease (1.053 1.2961.595 ), time on dialysis (1.005 1.0071.009 ), retransplantation (1.035 1.3971.885 ), preformed anti-HLA antibodies (1.011 1.3831.892 ), HLA mismatches (1.006 1.0661.130 ), donor age (1.011 1.0171.023 ), donor final serum creatinine (sCr) (1.239 1.3171.399 ), cold ischemia time (CIT) (1.031 1.0431.056 ), machine perfusion (0.401 0.5420.733 ), and induction therapy with rabbit antithymocyte globulin (rATG) (0.658 0.8000.973 ). Duration of DGF > 4 days was associated with inferior renal function and DGF > 14 days with the higher incidences of acute rejection, graft loss, and death. In conclusion, the incidence and duration of DGF were high and associated with inferior graft outcomes. While late referral and poor donor maintenance account for the high overall incidence of DGF, variability in donor and recipient selection, organ preservation method, and type of induction agent may account for the wide variation observed among transplant centers.

A large, international study on post-transplant glomerular diseases: the TANGO project.

BACKGROUND: Long-term outcomes in kidney transplantation (KT) have not significantly improved during the past twenty years. Despite being a leading cause of graft failure, glomerular disease (GD) recurrence remains poorly understood, due to heterogeneity in disease pathogenesis and clinical presentation, reliance on histopathology to confirm disease recurrence, and the low incidence of individual GD subtypes. Large, international cohorts of patients with GD are urgently needed to better understand the disease pathophysiology, predictors of recurrence, and response to therapy. METHODS: The Post-TrANsplant GlOmerular Disease (TANGO) study is an observational, multicenter cohort study initiated in January 2017 that aims to: 1) characterize the natural history of GD after KT, 2) create a biorepository of saliva, blood, urine, stools and kidney tissue samples, and 3) establish a network of patients and centers to support novel therapeutic trials. The study includes 15 centers in America and Europe. Enrollment is open to patients with biopsy-proven GD prior to transplantation, including IgA nephropathy, membranous nephropathy, focal and segmental glomerulosclerosis, atypical hemolytic uremic syndrome, dense-deposit disease, C3 glomerulopathy, complement- and IgG-positive membranoproliferative glomerulonephritis or membranoproliferative glomerulonephritis type I-III (old classification). During phase 1, patient data will be collected in an online database. The biorepository (phase 2) will involve collection of samples from patients for identification of predictors of recurrence, biomarkers of disease activity or response to therapy, and novel pathogenic mechanisms. Finally, through phase 3, we will use our multicenter network of patients and centers to launch interventional studies. DISCUSSION: Most prior studies of post-transplant GD recurrence are single-center and retrospective, or rely upon registry data that frequently misclassify the cause of kidney disease. Systematically determining GD recurrence rates and predictors of clinical outcomes is essential to improving post-transplant outcomes. Furthermore, accurate molecular phenotyping and biomarker development will allow better understanding of individual GD pathogenesis, and potentially identify novel drug targets for GD in both native and transplanted kidneys. The TANGO study has the potential to tackle GD recurrence through a multicenter design and a comprehensive biorepository.

Analysis of economic impact between the modality of renal replacement therapy / Análise do impacto econômico entre as modalidades de terapia renal substitutiva

Abstract Introduction: Chronic kidney disease (CKD) is a major health problem, determining the reduction in life expectancy and an increased risk of cardiovascular disease. Method: An observational, cohort, retrospective, based on patient's medical records data with CKD under hemodialysis, peritoneal dialysis and kidney transplantation in the city of Curitiba, in the period from January to June 2014, evacuativo the financial impact on the Unified Health System (SUS) and the supplementary health. Results: The lowest cost of a kidney transplant in the first year was R$ 40,743.03 when cyclosporine was used and the highest was R$ 48,388.17 with the use of tacrolimus. In the second year post-transplant, hemodialysis and peritoneal dialysis have a higher cost compared to kidney transplant. Transplantation with deceased donor, treated with tacrolimus: R$ 67,023.39; Hemodialysis R$ 71,717.51 and automated peritoneal dialysis automatic R$ 69,527.03. Conclusions: After the first two years of renal replacement therapy, transplantation demonstrates lower costs to the system when compared to other modalities evaluated. Based on that, this therapy justifies improvements in government policies in this sector.

Resumo Introdução: A doença renal crônica (DRC) é um grande problema de saúde, determina redução na expectativa de vida e aumento dos riscos de doenças cardiovasculares. Método: Estudo observacional, de coorte, retrospectivo, baseado em dados de prontuários de pacientes com DRC em hemodiálise, diálise peritoneal e transplante renal na cidade de Curitiba, no período de janeiro a junho de 2014, avaliando o impacto financeiro no Sistema Único de Saúde (SUS) e na saúde suplementar. Resultados: O menor custo de um transplante renal no primeiro ano foi de R$ 40.743,03, quando utilizada a ciclosporina, e o maior de R$ 48.388,17, com a utilização do tacrolimo. Já no segundo ano pós-transplante, a hemodiálise e a diálise peritoneal têm valor superior ao transplante renal. Transplante com doador falecido, com tacrolimo: R$ 67.023,39; hemodiálise R$ 71.717,51 e diálise peritoneal automática R$ 69.527,03. Conclusões: Após os dois primeiros anos da terapia renal substitutiva, o transplante demonstra menores custos ao sistema, quando comparado às outras modalidades avaliadas. Baseado nisso, esta terapia justifica melhorias nas políticas governamentais nesse setor.

Analysis of economic impact between the modality of renal replacement therapy.

INTRODUCTION: Chronic kidney disease (CKD) is a major health problem, determining the reduction in life expectancy and an increased risk of cardiovascular disease. METHOD: An observational, cohort, retrospective, based on patient's medical records data with CKD under hemodialysis, peritoneal dialysis and kidney transplantation in the city of Curitiba, in the period from January to June 2014, evacuativo the financial impact on the Unified Health System (SUS) and the supplementary health. RESULTS: The lowest cost of a kidney transplant in the first year was R$ 40,743.03 when cyclosporine was used and the highest was R$ 48,388.17 with the use of tacrolimus. In the second year post-transplant, hemodialysis and peritoneal dialysis have a higher cost compared to kidney transplant. Transplantation with deceased donor, treated with tacrolimus: R$ 67,023.39; Hemodialysis R$ 71,717.51 and automated peritoneal dialysis automatic R$ 69,527.03. CONCLUSIONS: After the first two years of renal replacement therapy, transplantation demonstrates lower costs to the system when compared to other modalities evaluated. Based on that, this therapy justifies improvements in government policies in this sector.

Pelvic kidney for living transplantation: case report and review of the literature.

INTRODUCTION: The difference between available kidneys and the number of patients on waiting list for kidney transplantation continues to grow. For this reason the trend is to use donors with expanded criteria, such as a pelvic kidney, as we describe below. CASE REPORT: Male patient 25 years-old with end-stage kidney disease, receives as a graft a pelvic kidney from his father, 49 years-old, known to have controlled systemic arterial hypertension and nephrolithiasis by history without new episodes in the last 10 years. Function and anatomy of the pelvic kidney were evaluated through magnetic angioressonance, computerized tomography and scintigraphy. After an initial rejection episode promptly treated, the patient has had an uneventful recovery. CONCLUSION: To increase the number of kidneys available for transplantation, it is reasonable to use a pelvic kidney, after a thorough investigation.

Rim pélvico de doador vivo-relacionado para transplante: relato de caso e revisão da literatura / Pelvic kidney for living transplantation: case report and review of the literature

ResumoIntrodução:É cada vez maior a discrepância entre a fila de espera e a oferta para um transplante renal. Fica evidente a necessidade de se usar enxertos com critérios expandidos, como, por exemplo, rim pélvico, conforme relatamos a seguir.Relato de caso:Paciente masculino de 25 anos, com doença renal crônica estádio 5, recebe como enxerto rim pélvico do pai, 49 anos, com história prévia de hipertensão arterial sistêmica bem controlada e urolitíase há mais de 10 anos sem novos episódios. Função e anatomia do rim pélvico foram avaliadas com exames de imagem como ressonância magnética, tomografia computadorizada e cintilografia. Após rejeição inicial tratada adequadamente, paciente apresenta boa evolução.Conclusão:Para aumentar oferta de rins para doação, é possível a utilização de rim pélvico, desde que adequadamente estudado no pré-operatório.

AbstractIntroduction:The difference between available kidneys and the number of patients on waiting list for kidney transplantation continues to grow. For this reason the trend is to use donors with expanded criteria, such as a pelvic kidney, as we describe below.Case report:Male patient 25 years-old with end-stage kidney disease, receives as a graft a pelvic kidney from his father, 49 years-old, known to have controlled systemic arterial hypertension and nephrolithiasis by history without new episodes in the last 10 years. Function and anatomy of the pelvic kidney were evaluated through magnetic angioressonance, computarized tomography and scintigraphy. After an initial rejection episode promptly treated, the patient has had an uneventful recovery.Conclusion:To increase the number of kidneys available for transplantation, it is reasonable to use a pelvic kidney, after a thorough investigation.

Prevenção da Hipercalemia em pacientes em hemodiálise através de orientação dietética específica / Prevention of hyperkalemia in hemodialysis patients with specific dietary orientation

A Hipercalemia é bastante frequente em pacientes em hemodiálise, sendo um importante fator de morbidade e mortalidade. Neste estudo, verificou-se a ocorrência de prevalência de 23,3 por cento de hipercalemia na população em hemodiálise e redução dos valores do potássio sérico apenas após seis meses de orientação dietética e em um único mês. A identificação dos múltiplos foram determinantes de hipercalemia, bem como o prolongamento da orientação específica de alimentos ricos em potássio é necessária para validar o valor preventivo de sua aplicação

Fatores de risco para mortalidade em hemodiálise / Death risk factors in hemodialysis patients

Diversos estudos demonstraram a correlaçäo entre a adequacidade da hemodiálise, henatócrito, hipercalemia e ganho de peso interdialítico com a morbidade e mortalidade de pacientes renais crônicos. A quantificaçäo de tais ocorrências na unidade de hemodiálise da Irmandade da Santa Casa de Misericórdia de Curitiba, permite o estabelecimento de medidas corretivas como parte de um programa de controle de qualidade. Desta forma, este estudo objetivou identificar a ocorrência de alguns fatores de risco para mortalidade em hemodiálise visando estabelecer as medidas corretivas necessárias em nosso meio, através de estudo retrospectivo comparativo dos valores de Kt/C (índice de quantificaçäo de hemodiálise), ganho de peso interdialítico 9GPID), potássio e hematócrito em um intervalo de 6 meses entre a populaçäo em hemodiálise que foi a óbito (35 pacientes) com uma amostra pareada quanto a sexo, idade e co-morbidadeassociada em programa de hemodiálise. Os dados obtidos foram submetidos a análise estatística descritiva e ao teste z (análise das diferenças das médias). Observou-se que a principal causa de mortalidade de pacientes em hemodiálise foi cardiovascular (51,42 por cento) e que a média do GPID e do potássio sérico säo maiores no grupo óbito do que no controle e que a média de Kt/V e hematócrito säo menores no grupo óbito que no controle. Em nosso meio, GPID mais alto, hipercalemia, valores de hematócritos e Kt/V mais baixos ocorrem de modo mais significativo no grupo de pacientes que evoluem à óbito. Assim sendo, a atuaçäo tempo efetiva sobre estes fatores pode vir a minimizar as taxas de mortalidade em hemodiálise neste serviço